Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen-binding proteins

An alpha antagonist and antagonist technology, which can be used in drug combinations, antibodies, fusion polypeptides, etc., to solve problems such as blood vessel growth, hemorrhage and edema, and loss

Inactive Publication Date: 2012-05-16
GLAXO GRP LTD
View PDF45 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This in turn leads to abnormal blood vessel growth, hemorrhage and edema, tissue damage and vision loss

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen-binding proteins
  • Antigen-binding proteins
  • Antigen-binding proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0338] 1.1 Preparation of dual targeting anti-TNFα / anti-VEGF mAbdAb (DMS4000)

[0339] An anti-TNFα / anti-VEGF mAbdAb (designated DMS4000) was produced by fusing the dAb to the C-terminus of the mAb (adalimumab) heavy chain. To construct the heavy chain expression cassette, the vector DNA encoding the heavy chain of the alternative mAbdAb was used as a starting point. The dAb portion was excised using restriction enzymes SalI and HindIII. DOM15-26-593 (anti-VEGF dAb) was amplified by PCR (using primers encoding SalI and HindIII ends) and ligated into the vector backbone from which the dAb had been excised using the same restriction sites to generate mAb and dAb 'STG' (serine, threonine, glycine) linker between.

[0340] Sequence-verified clones (SEQ ID NO: 11 and 13 for the light and heavy chains, respectively) were selected and large-scale DNA preparations were performed and, using transient transfection techniques, passed through the light and heavy chains (SEQ ID NO: Co...

Embodiment 2

[0359] Biacore analysis of dual targeting anti-TNFα / anti-VEGF mAbdAb

[0360] Experimental mAbdAbs were subjected to BIAcore analysis to determine their kinetic association and dissociation constants for binding their corresponding antigens. at BIAcore TM 3000 devices for analysis. The equipment temperature was set at 25 °C. HBS-EP buffer was used as running buffer. Collect experimental data at the highest possible rate for the equipment. Using standard amine coupling chemistry according to the manufacturer's instructions, one flow cell on a research-grade CM5 chip was coated with protein A, and a second flow cell was similarly treated, but with buffer instead of protein A to generate a reference surface. A flow cell coated with Protein A was then used to capture mAbdAbs. Antigen was injected as 2x serial dilutions as detailed in Table 2. Several dilutions were run in duplicate. A separate buffer injection instead of ligand is used for background subtraction. Samples...

Embodiment 3

[0364] Stoichiometric assessment of antigen-binding proteins (using Biacore™)

[0365] This example is predictive. It provides guidance for conducting other assays in which the antigen binding proteins of the invention can be tested.

[0366] Anti-human IgG was immobilized on the CM5 biosensor chip by primary amine coupling. The antigen-binding protein is captured on this surface and then passed through with a single concentration of TNFα or VEGF sufficient to saturate the binding surface and the observed binding signal to full R-max. Then using the formula given, the stoichiometry is calculated:

[0367] Stoichiometry = Rmax*MW(ligand) / MW(analyte)*R(immobilized or captured ligand)

[0368] In cases where the stoichiometry of more than one analyte binding is calculated simultaneously, the different antigens are passed sequentially at saturating antigen concentrations and the stoichiometry is calculated as above. The work can be performed on a Biacore 3000 at 25°C using H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to combinations of TNFa antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNFa or a TNFa receptor and / or VEGF or a VEGF receptor.

Description

Background technique [0001] Vision loss has become a major health problem in developed economies. Blindness or poor vision affects more than 3 million US citizens over the age of 40, and this increases significantly with age. For example, those aged 80 or over make up approximately 8% of the US population, but nevertheless account for almost 70% of blindness. Common age-related eye diseases include age-related macular degeneration (AMD), cataracts, diabetic macular edema, retinal vein occlusion (RVO), and glaucoma. [0002] Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. There are 2 main clinical manifestations of AMD. Atrophic (dry) AMD is characterized by degeneration of the retinal pigment epithelium (RPE) and neuroretina. The early stages of atrophic AMD are associated with the formation of drusen beneath the RPE cell layer. Early atrophic AMD can develop into advanced disease in which the RPE degenerates completely and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/22C07K16/24A61P27/02C07K14/715
CPCC07K16/22C07K16/241C07K2319/00C07K2317/569C07K2317/21A61K39/3955A61K2039/507C07K2317/56A61P27/02A61P9/00A61P9/10A61K2300/00A61K39/395C07K14/715C07K16/24
Inventor P. 亚当森P. F. 埃尔特尔V. 格尔马谢夫斯基G. W. 高夫M. 斯图尔德
Owner GLAXO GRP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com